Anti‐angiogenic therapy is a cancer treatment strategy targeting new blood vessel formation. Microvessel density (MVD) is a histopathological method for evaluating angiogenesis and endoglin is used as an activated endothelial marker in human medicine. The assessment of the treatment effect using MVD is difficult because it is a non‐repeatable method. To develop a repeatable method for evaluating angiogenesis, we investigated correlations among MVD, mRNA transcription levels of endothelial markers and angiogenesis factors, and confirmed the agreement of mRNA transcription levels between tissue samples and small samples obtained by fine needle aspiration (FNA). The various types of spontaneous tumours were collected from 51 dogs. MVD was assessed by immunostaining for von Willebrand factor (vWF). mRNA transcription levels of vWF, endoglin, vascular endothelial growth factor (VEGF) and VEGF receptor‐2 (VEGFR2) were analysed using real‐time reverse transcription polymerase chain reaction (real‐time RT‐PCR). There were significant correlations between MVD and mRNA transcription levels of vWF, endoglin and VEGFR2. VEGFR2 was more strongly correlated with endoglin (P <.01, Rs = 0.649) than vWF (P <.01, Rs = 0.512), indicating that angiogenesis can be evaluated more accurately by the measurement of mRNA transcription levels of endoglin. The mRNA transcription levels in tissue and FNA samples were strongly correlated, suggesting that evaluating angiogenesis using FNA samples is possible. In conclusion, we developed a repeatable and objective method for angiogenesis evaluation using mRNA transcription levels of endothelial markers by FNA sampling.

中文翻译：

---

使用犬肿瘤中内皮糖蛋白表达的实时 RT-PCR 评估血管生成的可重复和客观的方法

抗血管生成疗法是一种针对新血管形成的癌症治疗策略。微血管密度 (MVD) 是一种评估血管生成的组织病理学方法，内皮糖蛋白在人类医学中被用作激活的内皮标志物。使用 MVD 评估治疗效果很困难，因为它是一种不可重复的方法。为了开发一种可重复的评估血管生成的方法，我们研究了 MVD、内皮标志物和血管生成因子的 mRNA 转录水平之间的相关性，并确认了组织样本和通过细针抽吸 (FNA) 获得的小样本之间 mRNA 转录水平的一致性。从51只狗中收集了各种类型的自发性肿瘤。通过血管性血友病因子 (vWF) 的免疫染色评估 MVD。vWF、内皮糖蛋白、使用实时逆转录聚合酶链反应 (real-time RT-PCR) 分析血管内皮生长因子 (VEGF) 和 VEGF 受体-2 (VEGFR2)。MVD 与 vWF、内皮糖蛋白和 VEGFR2 的 mRNA 转录水平之间存在显着相关性。VEGFR2 与内皮糖蛋白的相关性更强（P  <.01, Rs = 0.649) 比 vWF ( P  <.01, Rs = 0.512)，表明可以通过测量内皮糖蛋白的 mRNA 转录水平更准确地评估血管生成。组织和 FNA 样本中的 mRNA 转录水平密切相关，这表明使用 FNA 样本评估血管生成是可能的。总之，我们开发了一种可重复且客观的血管生成评估方法，通过 FNA 采样使用内皮标志物的 mRNA 转录水平。